Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VERSED vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Sedation,Anxiolysis,Amnesia,Induction of anesthesia,Maintenance of anesthesia,ICU sedation,Status epilepticus (off-label)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life: 1.8–2.5 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity (up to 8 hours), hepatic cirrhosis (up to 20 hours), and critically ill patients.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic via CYP3A4 isoenzymes; major metabolites include midazolam glucuronide (inactive) and alpha-hydroxymidazolam (active).
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: ~1% unchanged; Hepatic metabolism to glucuronide conjugates and 1-hydroxymidazolam, with subsequent renal elimination of metabolites. Fecal excretion is minimal (<2%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
97% bound primarily to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
1–1.5 L/kg (0.5–1.2 L/kg in adults); increased in obesity and hepatic disease, indicating extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
IM: 90%±; Oral: 40–50% (range 30–70%); Intranasal: ~75%; Rectal: ~50%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
e GFR 10-50 m L/min: No dose adjustment needed but monitor for prolonged sedation. e GFR <10 m L/min: Consider 50% dose reduction and monitor closely.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce dose by 75%.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Neonates: IV 0.05-0.1 mg/kg; max 0.15 mg/kg. Children: IV 0.025-0.05 mg/kg (max 2 mg); titrate. Oral 0.25-0.5 mg/kg (max 20 mg) for sedation. IM 0.07-0.08 mg/kg.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
IV: Initial 0.5-1 mg over 2 minutes; titrate slowly; max total dose 3.5 mg. Oral: 5 mg preoperatively. Reduced clearance necessitates careful titration.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Intravenous administration may cause respiratory depression and arrest, especially when used with opioids. Resuscitation equipment and skilled personnel must be available. Do not administer by rapid bolus injection.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression, hypotension, paradoxical reactions, dependence and withdrawal, use in elderly or debilitated patients, hepatic/renal impairment, myasthenia gravis, glaucoma, pregnancy (category D).
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to benzodiazepines, acute narrow-angle glaucoma, severe respiratory insufficiency (COPD), pregnancy (labor and delivery), breastfeeding (caution).
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Grapefruit juice inhibits CYP3A4 and can significantly increase midazolam plasma concentrations, prolonging sedation and respiratory depression. Avoid grapefruit products for at least 24 hours before and after administration. High-fat meals may reduce absorption rate but not extent, though clinical significance is minimal.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Midazolam is classified as FDA Pregnancy Category D. There is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. First trimester exposure may be associated with an increased risk of congenital malformations (e.g., cleft palate). Second and third trimester exposure may cause fetal CNS depression, respiratory depression, and withdrawal symptoms (floppy infant syndrome). Use during labor may cause neonatal respiratory depression and hypotonia. Maternal hypotension and decreased uterine blood flow may occur.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Midazolam is excreted in human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05 to 0.15. Relative infant dose is estimated to be <1% of maternal weight-adjusted dose. Due to potential for accumulation and CNS effects in the neonate, caution is advised; alternative agents with shorter half-lives and no active metabolites are preferred. Use only if clearly needed and monitor infant for sedation, poor feeding, and respiratory depression.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific standardized dose adjustments are established for pregnancy. Due to increased volume of distribution and altered protein binding, higher or more frequent doses may be required to achieve the same clinical effect. However, increased sensitivity to CNS depression and respiratory depression in pregnancy may offset this, requiring careful titration. Avoid use in first trimester if possible. Use lowest effective dose for shortest duration. During labor, use reduced doses due to potential for fetal accumulation and neonatal respiratory depression.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Midazolam (Versed) is a short-acting benzodiazepine used for procedural sedation, pre-anesthetic medication, and status epilepticus. It has amnestic properties. Onset is rapid (1-2 min IV, 15-30 min IM). Flumazenil is the reversal agent. Caution in elderly, hepatic impairment, and respiratory compromise. CYP3A4 inhibitors (e.g., macrolides, azole antifungals, grapefruit juice) increase levels. Not recommended for prolonged sedation in ICU due to active metabolites and accumulation.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
You may experience drowsiness, dizziness, or amnesia after receiving this medication.,Do not drive or operate heavy machinery for at least 24 hours after the procedure.,Avoid alcohol for at least 24 hours after receiving midazolam.,Grapefruit and grapefruit juice may increase the effects of midazolam; avoid consumption.,Inform your healthcare provider if you are pregnant, breastfeeding, or have a history of glaucoma or breathing problems.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VERSED vs ACTIQ, answered by our medical review team.
VERSED is a Benzodiazepine that works by Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VERSED and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VERSED is: IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VERSED and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VERSED is classified as Category C. Midazolam is classified as FDA Pregnancy Category D. There is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.